trending Market Intelligence /marketintelligence/en/news-insights/trending/ktbw3lmjxvmgiwl26ma2lw2 content esgSubNav
In This List

Biogen to no longer pursue development of blockbuster drug as stroke treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Biogen to no longer pursue development of blockbuster drug as stroke treatment

Biogen Inc. said it will no longer pursue development of natalizumab as a treatment for acute ischemic stroke.

An ischemic stroke is characterized by the sudden loss of blood circulation to an area of the brain, resulting in a corresponding loss of neurologic function.

The decision is based on the results of a mid-stage study known as Action 2, which enrolled 270 patients. The phase 2b study failed to meet its main goal of showing a meaningful improvement in outcomes when compared to placebo.

The study was a follow up to the original Action trial, which suggested natalizumab improved clinical outcomes when compared with placebo.

Biogen noted that the results of the study do not affect the benefit-risk profile of the drug in approved indications, including multiple sclerosis.

Natalizumab is market as Tysabri for the treatment of multiple sclerosis and Crohn's disease. The drug generated $2 billion in full-year 2017 revenues.